New drug shows promise for Tough-to-Treat myeloma in Long-Term study

NCT ID NCT06479954

Ongoing Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at the long-term safety and effectiveness of the drug elranatamab in people with relapsed and refractory multiple myeloma, a type of blood cancer that has not responded to other treatments. The study tracks side effects like cytokine release syndrome and nerve-related issues, as well as how well the drug controls the cancer. Only one patient is enrolled, so the results are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: elranatamab
What this could lead to: If successful, this study could confirm that elranatamab is a safe and effective long-term treatment option for people with hard-to-treat multiple myeloma.
What could go wrong: This is a very small study (only 1 participant) and is observational, so results may not apply to others. It focuses on safety monitoring, not proving a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED AND REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Contacts and locations

Locations

Pfizer

Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.